Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (36)
Amany Digal Ladagu, Funmilayo Eniola Olopade, Adeboye Adejare & James Olukayode Olopade. (2023) GluN2A and GluN2B N-Methyl-D-Aspartate Receptor (NMDARs) Subunits: Their Roles and Therapeutic Antagonists in Neurological Diseases. Pharmaceuticals 16:11, pages 1535.
Crossref
Crossref
Gehua Wen, Xiaoni Zhan, Xiaoming Xu, Xi Xia, Shukun Jiang, Xinghua Ren, Weishu Ren, Haoyang Lou, Lei Lu, Anca Hermenean, Jun Yao, Lina Gao, Baoman Li, Yan Lu & Xu Wu. (2023) Ketamine Improves the Glymphatic Pathway by Reducing the Pyroptosis of Hippocampal Astrocytes in the Chronic Unpredictable Mild Stress Model. Molecular Neurobiology.
Crossref
Crossref
He Chen, Yuanping Dong, Yun Wu & Feng Yi. (2023) Targeting NMDA receptor signaling for therapeutic intervention in brain disorders. Reviews in the Neurosciences 34:6, pages 635-647.
Crossref
Crossref
Karolina Podkowa, Kamil Czarnacki, Agnieszka Borończyk, Michał Borończyk & Justyna Paprocka. (2023) The NMDA receptor antagonists memantine and ketamine as anti-migraine agents. Naunyn-Schmiedeberg's Archives of Pharmacology 396:7, pages 1371-1398.
Crossref
Crossref
Thanasis Mitsis, Eleni Papakonstantinou & Dimitrios Vlachakis. (2023) Biological mechanisms underlying depression, epigenetics and their interplay (Review). International Journal of Epigenetics 3:1.
Crossref
Crossref
Anderson Camargo, Ana P. Dalmagro, Glorister A. Altê, Ana Lúcia B. Zeni, Carla I. Tasca & Ana Lúcia S. Rodrigues. (2023) NMDA receptor-mediated modulation on glutamine synthetase and glial glutamate transporter GLT-1 is involved in the antidepressant-like and neuroprotective effects of guanosine. Chemico-Biological Interactions 375, pages 110440.
Crossref
Crossref
Timothy Fitzgerald, Maryia Zhdanava, Dominic Pilon, Aditi Shah, Annalise Hilts, Patrick Lefebvre & Steven R. Feldman. (2023) Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA. Dermatology and Therapy 13:4, pages 1053-1068.
Crossref
Crossref
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, Jessica R. Gilbert, Ioline D. Henter & Carlos A. ZarateJr.Jr.. (2023) Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. Neuropharmacology 226, pages 109422.
Crossref
Crossref
Yu Qin, Xinlei Guo, Wenyue Song, Zehuai Liang, Yahui Wang, Dan Feng, Yiru Yang, Mingxing Li & Mingqi Gao. (2023) Antidepressant-like effect of CP-101,606: Evidence of mTOR pathway activation. Molecular and Cellular Neuroscience 124, pages 103821.
Crossref
Crossref
Francisco Donoso, John F. Cryan, Loreto Olavarría‐Ramírez, Yvonne M. Nolan & Gerard Clarke. (2022) Inflammation, Lifestyle Factors, and the Microbiome‐Gut‐Brain Axis: Relevance to Depression and Antidepressant Action. Clinical Pharmacology & Therapeutics 113:2, pages 246-259.
Crossref
Crossref
Richard T. Beresis. 2022. Current Drug Synthesis. Current Drug Synthesis
265
286
.
Sylwia Samojedny, Ewelina Czechowska, Patrycja Pańczyszyn-Trzewik & Magdalena Sowa-Kućma. (2022) Postsynaptic Proteins at Excitatory Synapses in the Brain—Relationship with Depressive Disorders. International Journal of Molecular Sciences 23:19, pages 11423.
Crossref
Crossref
Hong Qian, Chang Shu, Ling Xiao & Gaohua Wang. (2022) Histamine and histamine receptors: Roles in major depressive disorder. Frontiers in Psychiatry 13.
Crossref
Crossref
Chenchen Bi, Shitian Guo, Shijia Hu, Jiaqi Chen, Mengfei Ye & Zheng Liu. (2022) The microbiota–gut–brain axis and its modulation in the therapy of depression: Comparison of efficacy of conventional drugs and traditional Chinese medicine approaches. Pharmacological Research 183, pages 106372.
Crossref
Crossref
Bartłomiej Pochwat, Paulina Misztak, Julia Masternak, Ewa Bączyńska, Krystian Bijata, Matylda Roszkowska, Monika Bijata, Jakub Włodarczyk, Małgorzata Szafarz, Elżbieta Wyska, Bożena Muszyńska, Agata Krakowska, Włodzimierz Opoka, Gabriel Nowak & Bernadeta Szewczyk. (2022) Combined hyperforin and lanicemine treatment instead of ketamine or imipramine restores behavioral deficits induced by chronic restraint stress and dietary zinc restriction in mice. Frontiers in Pharmacology 13.
Crossref
Crossref
Estela Saez, Leire Erkoreka, Teresa Moreno-Calle, Belen Berjano, Ana Gonzalez-Pinto, Nieves Basterreche & Aurora Arrue. (2022) Genetic variables of the glutamatergic system associated with treatment-resistant depression: A review of the literature. World Journal of Psychiatry 12:7, pages 884-896.
Crossref
Crossref
Ariana Pérez‐Pereira, Cláudia Ribeiro, Filomena Teles, Ricardo Gonçalves, Virgínia M.F. Gonçalves, José Augusto Pereira, João Soares Carrola, Carlos Pires & Maria Elizabeth Tiritan. (2021) Ketamine and Norketamine: Enantioresolution and Enantioselective Aquatic Ecotoxicity Studies. Environmental Toxicology and Chemistry 41:3, pages 569-579.
Crossref
Crossref
Thomas J.P. Mangnus, Krishna D. Bharwani, Dirk L. Stronks, Maaike Dirckx & Frank J.P.M. Huygen. (2022) Ketamine therapy for chronic pain in The Netherlands: a nationwide survey. Scandinavian Journal of Pain 22:1, pages 97-105.
Crossref
Crossref
Susan Ling, Felicia Ceban, Leanna M. W. Lui, Yena Lee, Kayla M. Teopiz, Nelson B. Rodrigues, Orly Lipsitz, Hartej Gill, Mehala Subramaniapillai, Rodrigo B. Mansur, Kangguang Lin, Roger Ho, Joshua D. Rosenblat, David Castle & Roger S. McIntyre. (2021) Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. CNS Drugs 36:1, pages 17-30.
Crossref
Crossref
Thomas J. P. Mangnus, Maaike Dirckx, Krishna D. Bharwani, Cecile C. Vos, Sander P. G. Frankema, Dirk L. Stronks & Frank J. P. M. Huygen. (2021) Effect of intravenous low‐dose S‐ketamine on pain in patients with Complex Regional Pain Syndrome: A retrospective cohort study. Pain Practice 21:8, pages 890-897.
Crossref
Crossref
Ewa Bromek, Anna Haduch, Marta Rysz, Joanna Jastrzębska, Renata Pukło, Olga Wójcikowska, Przemysław Jan Danek & Władysława Anna Daniel. (2021) The Selective NMDA Receptor GluN2B Subunit Antagonist CP-101,606 with Antidepressant Properties Modulates Cytochrome P450 Expression in the Liver. Pharmaceutics 13:10, pages 1643.
Crossref
Crossref
Ya-Ting Wang, Xiao-Le Wang, Si-Tong Feng, Nai-Hong Chen, Zhen-Zhen Wang & Yi Zhang. (2021) Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression. Pharmacological Research 171, pages 105761.
Crossref
Crossref
Lehel Balogh, Masaru Tanaka, Nóra Török, László Vécsei & Shigeru Taguchi. (2021) Crosstalk between Existential Phenomenological Psychotherapy and Neurological Sciences in Mood and Anxiety Disorders. Biomedicines 9:4, pages 340.
Crossref
Crossref
Zhiqing Zhan, Xichao Wang, Qing Chen, Zhidai Xiao & Bin Zhang. (2021) Comparative efficacy and side-effect profile of ketamine and esketamine in the treatment of unipolar and bipolar depression: protocol for a systematic review and network meta-analysis. BMJ Open 11:2, pages e043457.
Crossref
Crossref
Sandeep K. Mishra, Mahendra Kumar Hidau & Shivika Rai. (2021) Memantine treatment exerts an antidepressant-like effect by preventing hippocampal mitochondrial dysfunction and memory impairment via upregulation of CREB/BDNF signaling in the rat model of chronic unpredictable stress-induced depression. Neurochemistry International 142, pages 104932.
Crossref
Crossref
Michele Fornaro, Domenico De Berardis, Annalisa Anastasia & Andrea Fusco. 2021. Major Depressive Disorder. Major Depressive Disorder
449
461
.
Piper A. Ranallo & Jessica D. Tenenbaum. 2021. Mental Health Informatics. Mental Health Informatics
1
30
.
Diana M. Ciuculete, Sarah Voisin, Lara Kular, Jörgen Jonsson, Mathias Rask-Andersen, Jessica Mwinyi & Helgi B. Schiöth. (2020) meQTL and ncRNA functional analyses of 102 GWAS-SNPs associated with depression implicate HACE1 and SHANK2 genes. Clinical Epigenetics 12:1.
Crossref
Crossref
Maryam Anjomshoa, Shakiba N. Boroujeni, Esmaeel Bagheri, Zahra Lorigooini & Hossein Amini-Khoei. (2020) Possible Involvement of N-methyl-D-aspartate Receptor (NMDA-R) in the Antidepressant- like Effect of Trigonelline in Male Mice. Current Pharmaceutical Design 26:39, pages 5067-5071.
Crossref
Crossref
Zhujin Song, Fengming Shen, Zhengrong Zhang, Shengbing Wu & Guoqi Zhu. (2020) Calpain inhibition ameliorates depression-like behaviors by reducing inflammation and promoting synaptic protein expression in the hippocampus. Neuropharmacology 174, pages 108175.
Crossref
Crossref
Bartłomiej Pochwat, Helena Domin, Anna Rafało-Ulińska, Bernadeta Szewczyk & Gabriel Nowak. (2020) Ketamine and Ro 25-6981 Reverse Behavioral Abnormalities in Rats Subjected to Dietary Zinc Restriction. International Journal of Molecular Sciences 21:13, pages 4791.
Crossref
Crossref
Xiao Han Zou, Li Hua Sun, Wei Yang, Bing Jin Li & Ran Ji Cui. (2020) Potential role of insulin on the pathogenesis of depression. Cell Proliferation 53:5.
Crossref
Crossref
Margarida Espadinha, Lucía Viejo, Ricardo M.R.M. Lopes, Clara Herrera-Arozamena, Elies Molins, Daniel J.V.A. dos Santos, Lídia Gonçalves, María Isabel Rodríguez-Franco, Cristóbal de los Ríos & Maria M.M. Santos. (2020) Identification of tetracyclic lactams as NMDA receptor antagonists with potential application in neurological disorders. European Journal of Medicinal Chemistry 194, pages 112242.
Crossref
Crossref
Domenico De Berardis, Carmine Tomasetti, Maurizio Pompili, Gianluca Serafini, Federica Vellante, Michele Fornaro, Alessandro Valchera, Giampaolo Perna, Umberto Volpe, Giovanni Martinotti, Silvia Fraticelli, Massimo Di Giannantonio, Yong-Ku Kim & Laura Orsolini. (2020) An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine. Current Topics in Medicinal Chemistry 20:7, pages 554-584.
Crossref
Crossref
Ana González-Pinto. (2020) Esketamina intranasal: un nuevo abordaje para el tratamiento de la depresión resistente al tratamiento. Psiquiatría Biológica 27:1, pages 9-15.
Crossref
Crossref
William J. Lorman. (2019) Pharmacology Corner. Journal of Addictions Nursing 30:4, pages 282-283.
Crossref
Crossref